SCHEMBL20072836

SCHEMBL20072836

C=C(CI)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.48
CES1 P23141 2/20 0.48
PTPN1 P18031 2/20 0.46
GSK3B P49841 2/20 0.46
SRD5A2 P31213 2/20 0.42
MMP1 P03956 1/20 0.40
TRPV1 Q8NER1 1/20 0.40
ORAI1 Q96D31 1/20 0.39
ORAI2 Q96SN7 1/20 0.39
ORAI3 Q9BRQ5 1/20 0.39
TRPV6 Q9H1D0 1/20 0.39
KIF11 P52732 1/20 0.39
MGLL Q99685 1/20 0.39
NR4A1 P22736 1/20 0.38
NR4A2 P43354 1/20 0.38
NR4A3 Q92570 1/20 0.38
GRIN2B Q13224 1/20 0.38
MEN1 O00255 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3588964 0.81 CES2 (0.50) CES2CES1PTPN1GSK3BSRD5A2
SCHEMBL28982625 0.79 CES2 (0.48) CES2CES1PTPN1GSK3BSRD5A2
SCHEMBL1475613 0.79 CES2 (0.48) CES2CES1PTPN1GSK3BSRD5A2
SCHEMBL21294692 0.77 CES2 (0.55) CES2SRD5A2MGLLMEN1HPGD
SCHEMBL22746994 0.76 CES2 (0.54) CES2CES1PTPN1GSK3BSRD5A2
SCHEMBL5367277 0.75 GSK3B (0.66) CES2CES1PTPN1GSK3BSRD5A2
SCHEMBL28243558 0.75 CES2 (0.58) CES2CES1PTPN1GSK3BSRD5A2
SCHEMBL21294838 0.73 CES2 (0.38) CES2HDAC1
SCHEMBL28402017 0.73 CES2 (0.56) CES2CES1PTPN1GSK3BSRD5A2
SCHEMBL928167 0.71 CES2 (0.54) CES2CES1PTPN1GSK3BSRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200115354-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2020-04-16 US disclosed
US-20200115354-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2020-04-16 US disclosed
US-10457654-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2019-10-29 US disclosed
US-10457654-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2019-10-29 US disclosed
WO-2018072602-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-04-26 WO disclosed
US-20180105504-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-04-19 US disclosed
US-20180105504-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200115354-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF NPY5R, REN, F12 CES2 966/4885CES1 1145/4885PTPN1 909/4885
US-10457654-B2 Therapeutic compounds and methods of use thereof NPY5R, REN, F12 CES2 966/4885CES1 1145/4885PTPN1 909/4885
US-20180105504-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF NPY5R, REN, F12 CES2 1001/4885CES1 1212/4885PTPN1 905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.